Literature DB >> 15162553

Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.

Tatehiro Kagawa1, Norihito Watanabe, Hisashi Kanouda, Ichiro Takayama, Tadahiko Shiba, Takashi Kanai, Kazuya Kawazoe, Shinji Takashimizu, Nobue Kumaki, Kazuo Shimamura, Shohei Matsuzaki, Tetsuya Mine.   

Abstract

We report a case of fatal liver failure due to reactivation of lamivudine-resistant HBV. A 53-year-old man was followed since 1998 for HBV-related chronic hepatitis. Serum HBV-DNA was 150 MEq/mL (branched DNA signal amplification assay) and ALT levels fluctuated between 50-200 IU/L with no clinical signs of liver cirrhosis. Lamivudine (100 mg/d) was started in May 2001 and serum HBV-DNA subsequently decreased below undetectable levels. In May 2002, serum HBV-DNA had increased to 410 MEq/mL, along with ALT flare (226 IU/L). The YMDD motif in the DNA polymerase gene had been replaced by YIDD. Lamivudine was continued and ALT spontaneously decreased to the former levels. On Oct 3 the patient presenting with general fatigue, nausea and jaundice was admitted to our hospital. The laboratory data revealed HBV reactivation and liver failure (ALT: 1828 IU/L, total bilirubin: 10 mg/dL, and prothrombin INR: 3.24). For religious reasons, the patient and his family refused blood transfusion, plasma exchange and liver transplantation. The patient died 10 d after admission. The autopsy revealed remarkable liver atrophy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162553      PMCID: PMC4572782          DOI: 10.3748/wjg.v10.i11.1686

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

1.  Hepatitis B therapy: the plot thickens.

Authors:  A H Malik; W M Lee
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

2.  Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

Authors:  Maurizio Bonacini; Alan Kurz; Stephen Locarnini; Anna Ayres; Craig Gibbs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

3.  Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

Authors:  J W Kim; H S Lee; G H Woo; J H Yoon; J J Jang; J G Chi; C Y Kim
Journal:  Clin Infect Dis       Date:  2001-07-07       Impact factor: 9.079

4.  Acarbose-induced hepatic injury.

Authors:  Y Fujimoto; M Ohhira; N Miyokawa; S Kitamori; Y Kohgo
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

5.  Acarbose-induced acute severe hepatotoxicity.

Authors:  M Carrascosa; F Pascual; S Aresti
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

6.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.

Authors:  Y F Liaw; R N Chien; C T Yeh; S L Tsai; C M Chu
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

7.  Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Authors:  R Perrillo; E Schiff; E Yoshida; A Statler; K Hirsch; T Wright; K Gutfreund; P Lamy; A Murray
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

8.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

9.  The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

Authors:  R A de Man; A I Bartholomeusz; H G Niesters; P E Zondervan; S A Locarnini
Journal:  J Hepatol       Date:  1998-10       Impact factor: 25.083

10.  Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay.

Authors:  D A Hendricks; B J Stowe; B S Hoo; J Kolberg; B D Irvine; P D Neuwald; M S Urdea; R P Perrillo
Journal:  Am J Clin Pathol       Date:  1995-11       Impact factor: 2.493

  10 in total
  8 in total

1.  Relationship between body surface area and ALT normalization after long-term lamivudine treatment.

Authors:  Makoto Nakamuta; Shusuke Morizono; Yuichi Tanabe; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Norihiro Furusyo; Hideyuki Nomura; Hironori Sakai; Kazuhiro Takahashi; Koichi Azuma; Shinji Shimoda; Kazuhiro Kotoh; Munechika Enjoji; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  He Jie Tang in the treatment of chronic hepatitis B patients.

Authors:  Ze-Xiong Chen; Shi-Jun Zhang; Shao-Xian Lao; Hong-Tao Hu; Cui-Yi Zhang; Shi-He Guan; Yan-Li Gu
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

3.  Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report.

Authors:  Yuka Suzuki; Hiroshi Yotsuyanagi; Chiaki Okuse; Yoshihiko Nagase; Hideaki Takahashi; Kyoji Moriya; Michihiro Suzuki; Kazuhiko Koike; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

4.  Management of chronic hepatitis B in severe liver disease.

Authors:  James Fung; Ching-Lung Lai; Man-Fung Yuen
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 5.  Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure.

Authors:  En-Qiang Chen; Fan Zeng; Ling-Yun Zhou; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.

Authors:  Kang Mo Kim; Won-Beom Choi; Young-Suk Lim; Han-Chu Lee; Young-Hwa Chung; Young-Sang Lee; Dong-Jin Suh
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

7.  trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase.

Authors:  Richard A Heipertz; Jason L Starkey; Thomas G Miller; Jianming Hu; Harriet C Isom
Journal:  Virology       Date:  2009-04-19       Impact factor: 3.616

8.  Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients.

Authors:  Makoto Nakamuta; Kazuhiro Kotoh; Munechika Enjoji; Eiji Kajiwara; Junya Shimono; Akihide Masumoto; Toshihiro Maruyama; Norihiro Furusyo; Hideyuki Nomura; Hironori Sakai; Kazuhiro Takahashi; Koichi Azuma; Shinji Shimoda; Yuichi Tanabe; Jun Hayashi
Journal:  Comp Hepatol       Date:  2007-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.